Vilon

Quickstart Highlights

Vilon (Lys‑Glu) is a synthetic immunoregulatory dipeptide consisting of lysine and glutamic acid residues. Preclinical research indicates it may enhance immune markers including CD5+ lymphocytes and interleukin‑2 expression in thymic and splenic cell cultures. This educational protocol presents a once-daily subcutaneous course (10–20 consecutive days, repeated one to three times per year) using a practical dilution for clear insulin‑syringe measurements.

• Reconstitute: Add 3.0 mL bacteriostatic water → ~6.67 mg/mL concentration.
• Typical range: 100–1000 mcg once daily for a 10–20 day course (500 mcg standard; 100–200 mcg conservative start for the first 3 days; 1 mg upper limit); repeat 1–3 times per year, at least 3 months apart.
• Easy measuring: At 6.67 mg/mL, 1 unit = 0.01 mL ≈ 66.7 mcg on a U-100 insulin syringe; 500 mcg ≈ 7.5 units (needs half-unit markings), 1 mg = 15 units.
• Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); use within 1 week or aliquot and freeze.

Protocol Overview

Concise summary of the 10–20 day course regimen.

• Goal: Support immune modulation and thymic function markers based on preclinical observations.
• Schedule: One daily subcutaneous injection for a 10–20 day course (10-day short course, 20-day standard); repeat one to three times per year with at least 3 months between courses.
• Dose Range: 100–1000 mcg daily; 500 mcg standard, 100–200 mcg conservative start for the first 3 days, 1 mg upper limit.
• Reconstitution: 3.0 mL per 20 mg vial (~6.67 mg/mL) for accurate low‑volume measurements.
• Storage: Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze–thaw.

Dosing Protocol

Suggested 10–20 day course (Khavinson-style bioregulator schedule; 20 days standard).

• Start: 100–200 mcg (1.5–3 units) daily for Days 1–3 as a conservative start to assess tolerance (500 mcg from Day 1 is the standard course).
• Target: 500 mcg (7.5 units) daily from Day 4 through Day 20.
• Frequency: Once per day (subcutaneous).
• Course Length: 10–20 days (10-day short course, 20-day standard); 1–3 courses per year with at least 3 months between courses. Do not extend continuously.
• Timing: Any consistent time; rotate injection sites daily.
• Upper limit: 1000 mcg (1 mg; 15 units) daily; do not exceed.

Storage Instructions

Proper storage preserves peptide quality.

• Lyophilized: Store at −20 °C (−4 °F) short‑term or −80 °C (−112 °F) long‑term in dry, dark conditions; minimize moisture exposure.
• Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within ~1 week or prepare aliquots and freeze to extend stability.
• Allow vials to reach room temperature before opening to reduce condensation uptake.

Important Notes

Practical considerations for consistency and safety.

• Use new sterile insulin syringes (30‑ or 50‑unit recommended for low‑volume accuracy); dispose in a sharps container.
• Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation.
• Inject slowly; wait a few seconds before withdrawing the needle.
• Document daily dose and site rotation to maintain consistency across courses.

How This Works

Vilon belongs to a class of short bioregulatory peptides developed through Russian gerontology research. In vitro studies demonstrate that the Lys‑Glu dipeptide can modulate lymphocyte populations and cytokine gene expression. Specifically, Vilon has been observed to increase CD5+ cell counts in thymus cell cultures and upregulate interleukin‑2 (IL‑2) mRNA expression in splenocyte preparations. Additional preclinical work suggests effects on TGF‑β1 and vascular permeability in renal models. The 10–20 day course regimen follows the Khavinson bioregulator short-course convention used for related short peptides such as Epitalon.

Potential Benefits & Side Effects

Observations from preclinical literature.

• Supports immune cell marker expression (CD5+ lymphocytes) and IL‑2 gene activity in cell culture models.
• May modulate inflammatory cytokines such as TGF‑β1 under experimental renal stress conditions.
• Early mouse studies suggest potential effects on tumor growth inhibition and lifespan extension, though human data remain limited.
• Generally well tolerated in preclinical settings; occasional mild injection‑site reactions (redness/itch) may occur with subcutaneous administration.

Lifestyle Factors

Complementary strategies for best outcomes.

• Pair with a nutrient‑dense diet rich in antioxidants and adequate protein to support immune function.
• Incorporate regular moderate exercise to reinforce immune and metabolic health.
• Prioritize sleep (7–9 hours) and stress management to optimize endogenous immune regulation.

Injection Technique

General subcutaneous guidance from clinical best‑practice resources.

• Clean the vial stopper and skin with alcohol; allow to dry.
• Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue.
• Do not aspirate for subcutaneous injections; inject slowly and steadily.
• Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy.

Recommended Source

Note: Product availability and specifications subject to change. Verify current product details on supplier website.

Browse Amino Labs